Alcresta Therapeutics Comparisons
Developer of enzyme-based products designed to combat gastrointestinal disorders. The company's digestive enzyme cartrid
Alcresta Therapeutics Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Who is the MD of Alcresta Therapeutics?
NEWTON, MA, December 7, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the appointment of Alan Muney, MD to its Board of Directors. Dr. Muney is currently a senior healthcare advisor for Pritzker Private Capital, Arsenal Capital, Bain Management Consulting, and NEA Venture Capital.
What is Alcresta enzyme based?
Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital.
What is a rilizorb?
RELiZORB is a digestive enzyme cartridge designed to mimic the function of pancreatic lipase. RELiZORB helps children and adults on enteral tube feeding who have trouble breaking down and absorbing fats due to cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, and other rare diseases. REL i ZORB.
Is Alcresta Therapeutics a commercial company?
NEWTON, MA, November 11, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the publication of a 12-month observational study in Journal of Pediatric Gastroenterology & Nutrition that evaluated the effectiveness of long-term RELiZORB® (iMMOBILIZED LIPASE) Cartridge use in enterally fed patients with cystic fibrosis.
Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA
Refusal to File letters concern the new drug application for dovitinib and the DRP®-Dovitinib companion diagnostic pre-market approval applicationAllarity intends to seek guidance from the FDA on how to further advance dovitinib and its accompanying DRP®-Dovitinib companion diagnostic towards approval Press releaseCambridge, MA U.S.A.
Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S.
